Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
businesswire.com
news
2022-06-03 00:00:00

June 03, 2022 01:00 AM Eastern Daylight Time MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:



Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ('Innate' or the 'Company') today announced that IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), will advance into a Phase 2 clinical trial in lung cancer. Innate will receive a $5M milestone payment from AstraZeneca and will be responsible for conducting the study. AstraZeneca and Innate will share study costs and AstraZeneca will supply clinical trial drugs.
